Galectin-10 antibodies

Patent metadata

Field	Value
Publication number	US-11066473-B2
Application number	US-201916382997-A
Country	US
Kind code	B2
Filing date	Apr 12, 2019
Priority date	Apr 13, 2018
Publication date	Jul 20, 2021
Grant date	Jul 20, 2021

Abstract

The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).

First claim

The invention claimed is:

1. An antibody or antigen binding fragment thereof which binds to galectin-10, wherein the antibody or antigen binding fragment thereof comprises a combination of a heavy chain variable domain (VH) and a light chain variable domain (VL),
wherein the VH comprises the amino acid sequence of SEQ ID NO: 194, and the VL comprises the amino acid sequence of SEQ ID NO: 195.

2. A pharmaceutical composition comprising an antibody or antigen binding fragment according to claim 1 and at least one pharmaceutically acceptable carrier or excipient.

3. A kit comprising an antibody or antigen binding fragment according to claim 1 .

4. An antibody or antigen binding fragment thereof which binds to galectin-10, wherein the antibody or antigen binding fragment thereof comprises HCDR3 consisting of SEQ ID NO: 162; HCDR2 consisting of SEQ ID NO: 161; HCDR1 consisting of SEQ ID NO: 160; LCDR3 consisting of SEQ ID NO: 179; LCDR2 consisting of SEQ ID NO: 178; and LCDR1 consisting of SEQ ID NO: 177.

5. A pharmaceutical composition comprising an antibody or antigen binding fragment according to claim 4 and at least one pharmaceutically acceptable carrier or excipient.

6. A kit comprising an antibody or antigen binding fragment according to claim 4 .

7. An antibody or antigen binding fragment thereof which binds to galectin-10, wherein the antibody or antigen binding fragment comprises a variable heavy chain domain (VH) and a variable light chain domain (VL) wherein the VH and VL domains comprise the set of CDR sequences selected from the group consisting of:
(i) HCDR3 comprising or consisting of SEQ ID NO: 3; HCDR2 comprising or consisting of SEQ ID NO: 2; HCDR1 comprising or consisting of SEQ ID NO: 1; LCDR3 comprising or consisting of SEQ ID NO: 58; LCDR2 comprising or consisting of SEQ ID NO: 57; LCDR1 comprising or consisting of SEQ ID NO: 56;
(ii) HCDR3 comprising or consisting of SEQ ID NO: 6; HCDR2 comprising or consisting of SEQ ID NO: 5; HCDR1 comprising or consisting of SEQ ID NO: 4; LCDR3 comprising or consisting of SEQ ID NO: 61; LCDR2 comprising or consisting of SEQ ID NO: 60; LCDR1 comprising or consisting of SEQ ID NO: 59;
(iii) HCDR3 comprising or consisting of SEQ ID NO: 9; HCDR2 comprising or consisting of SEQ ID NO: 8; HCDR1 comprising or consisting of SEQ ID NO: 7; LCDR3 comprising or consisting of SEQ ID NO: 64; LCDR2 comprising or consisting of SEQ ID NO: 63; LCDR1 comprising or consisting of SEQ ID NO: 62;
(iv) HCDR3 comprising or consisting of SEQ ID NO: 12; HCDR2 comprising or consisting of SEQ ID NO: 11; HCDR1 comprising or consisting of SEQ ID NO: 10; LCDR3 comprising or consisting of SEQ ID NO: 67; LCDR2 comprising or consisting of SEQ ID NO: 66; LCDR1 comprising or consisting of SEQ ID NO: 65;
(v) HCDR3 comprising or consisting of SEQ ID NO: 15; HCDR2 comprising or consisting of SEQ ID NO: 14; HCDR1 comprising or consisting of SEQ ID NO: 13; LCDR3 comprising or consisting of SEQ ID NO: 70; LCDR2 comprising or consisting of SEQ ID NO: 69; LCDR1 comprising or consisting of SEQ ID NO: 68;
(vi) HCDR3 comprising or consisting of SEQ ID NO: 18; HCDR2 comprising or consisting of SEQ ID NO: 17; HCDR1 comprising or consisting of SEQ ID NO: 16; LCDR3 comprising or consisting of SEQ ID NO: 72; LCDR2 comprising or consisting of SEQ ID NO: 66; LCDR1 comprising or consisting of SEQ ID NO: 71;
(vii) HCDR3 comprising or consisting of SEQ ID NO: 20; HCDR2 comprising or consisting of SEQ ID NO: 19; HCDR1 comprising or consisting of SEQ ID NO: 4; LCDR3 comprising or consisting of SEQ ID NO: 75; LCDR2 comprising or consisting of SEQ ID NO: 74; LCDR1 comprising or consisting of SEQ ID NO: 73;
(viii) HCDR3 comprising or consisting of SEQ ID NO: 23; HCDR2 comprising or consisting of SEQ ID NO: 22; HCDR1 comprising or consisting of SEQ ID NO: 21; LCDR3 comprising or consisting of SEQ ID NO: 67; LCDR2 comprising or consisting of SEQ ID NO: 66; LCDR1 comprising or consisting of SEQ ID NO: 65;
(ix) HCDR3 comprising or consisting of SEQ ID NO: 25; HCDR2 comprising or consisting of SEQ ID NO: 24; HCDR1 comprising or consisting of SEQ ID NO: 4; LCDR3 comprising or consisting of SEQ ID NO: 78; LCDR2 comprising or consisting of SEQ ID NO: 77; LCDR1 comprising or consisting of SEQ ID NO: 76;
(x) HCDR3 comprising or consisting of SEQ ID NO: 28; HCDR2 comprising or consisting of SEQ ID NO: 27; HCDR1 comprising or consisting of SEQ ID NO: 26; LCDR3 comprising or consisting of SEQ ID NO: 67; LCDR2 comprising or consisting of SEQ ID NO: 66; LCDR1 comprising or consisting of SEQ ID NO: 79;
(xi) HCDR3 comprising or consisting of SEQ ID NO: 31; HCDR2 comprising or consisting of SEQ ID NO: 30; HCDR1 comprising or consisting of SEQ ID NO: 29; LCDR3 comprising or consisting of SEQ ID NO: 81; LCDR2 comprising or consisting of SEQ ID NO: 63; LCDR1 comprising or consisting of SEQ ID NO: 80;
(xii) HCDR3 comprising or consisting of SEQ ID NO: 33; HCDR2 comprising or consisting of SEQ ID NO: 32; HCDR1 comprising or consisting of SEQ ID NO: 1; LCDR3 comprising or consisting of SEQ ID NO: 84; LCDR2 comprising or consisting of SEQ ID NO: 83; LCDR1 comprising or consisting of SEQ ID NO: 82;
(xiii) HCDR3 comprising or consisting of SEQ ID NO: 36; HCDR2 comprising or consisting of SEQ ID NO: 35; HCDR1 comprising or consisting of SEQ ID NO: 34; LCDR3 comprising or consisting of SEQ ID NO: 87; LCDR2 comprising or consisting of SEQ ID NO: 86; LCDR1 comprising or consisting of SEQ ID NO: 85;
(xiv) HCDR3 comprising or consisting of SEQ ID NO: 38; HCDR2 comprising or consisting of SEQ ID NO: 11; HCDR1 comprising or consisting of SEQ ID NO: 37; LCDR3 comprising or consisting of SEQ ID NO: 78; LCDR2 comprising or consisting of SEQ ID NO: 63; LCDR1 comprising or consisting of SEQ ID NO: 88;
(xv) HCDR3 comprising or consisting of SEQ ID NO: 41; HCDR2 comprising or consisting of SEQ ID NO: 40; HCDR1 comprising or consisting of SEQ ID NO: 39; LCDR3 comprising or consisting of SEQ ID NO: 91; LCDR2 comprising or consisting of SEQ ID NO: 90; LCDR1 comprising or consisting of SEQ ID NO: 89;
(xvi) HCDR3 comprising or consisting of SEQ ID NO: 43; HCDR2 comprising or consisting of SEQ ID NO: 42; HCDR1 comprising or consisting of SEQ ID NO: 4; LCDR3 comprising or consisting of SEQ ID NO: 94; LCDR2 comprising or consisting of SEQ ID NO: 93; LCDR1 comprising or consisting of SEQ ID NO: 92;
(xvii) HCDR3 comprising or consisting of SEQ ID NO: 6; HCDR2 comprising or consisting of SEQ ID NO: 44; HCDR1 comprising or consisting of SEQ ID NO: 4; LCDR3 comprising or consisting of SEQ ID NO: 97; LCDR2 comprising or consisting of SEQ ID NO: 96; LCDR1 comprising or consisting of SEQ ID NO: 95;
(xviii) HCDR3 comprising or consisting of SEQ ID NO: 47; HCDR2 comprising or consisting of SEQ ID NO: 46; HCDR1 comprising or consisting of SEQ ID NO: 45; LCDR3 comprising or consisting of SEQ ID NO: 94; LCDR2 comprising or consisting of SEQ ID NO: 93; LCDR1 comprising or consisting of SEQ ID NO: 71;
(xix) HCDR3 comprising or consisting of SEQ ID NO: 50; HCDR2 comprising or consisting of SEQ ID NO: 49; HCDR1 comprising or consisting of SEQ ID NO: 48; LCDR3 comprising or consisting of SEQ ID NO: 96; LCDR2 comprising or consisting of SEQ ID NO: 63; LCDR1 comprising or consisting of SEQ ID NO: 95;
(xx) HCDR3 comprising or consisting of SEQ ID NO: 36; HCDR2 comprising or consisting of SEQ ID NO: 52; HCDR1 comprising or consisting of SEQ ID NO: 51; LCDR3 comprising or consisting of SEQ ID NO: 98; LCDR2 comprising or consisting of SEQ ID NO: 97; LCDR1 comprising or consisting of SEQ ID NO: 80; and
(xxi) HCDR3 comprising or consisting of SEQ ID NO: 55; HCDR2 comprising or consisting of SEQ ID NO: 54; HCDR1 comprising or consisting of SEQ ID NO: 53; LCDR3 comprising or consisting of SEQ ID NO: 81; LCDR2 comprising or consisting of SEQ ID NO: 93;

Assignees

• Argenx Iip Bv
• Vib Vzw
• Univ Gent

Inventors

• Percier Jean-Michel
• Blanchetot Christophe
• Saunders Michael
• De Haard Hans
• Van Der Woning Sebastian
• Persson Emma
• Lambrecht Bart
• Savvides Savvas
• Hammad Hamida
• Verstraete Kenneth

Classifications

• C07K2317/622

  Single chain antibody (scFv) · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• C07K16/2851 Primary

  against the lectin superfamily, e.g. CD23, CD72 · CPC title

• G01N33/6857

  Antibody fragments · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title